Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says

Executive Summary

FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai

You may also be interested in...



FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival

FDA's final guidance on cancer endpoints has dropped a discussion on clinical trial designs that provide no treatment or use a placebo control

FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival

FDA's final guidance on cancer endpoints has dropped a discussion on clinical trial designs that provide no treatment or use a placebo control

Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis

FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies

Related Content

Topics

UsernamePublicRestriction

Register

PS046195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel